A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease
Clinical trial NCT07023289 · RECRUITING
Trial details
- NCT number
- NCT07023289
- Sponsor
- AbbVie
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-09-02
- Primary completion
- 2029-11-01
- Enrollment
- 140
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.